Table 4

Associations of the biomarkers listed in table 2 with neurophysiological tests in the group with DSPN (n=304; PROPANE study). Only correlations achieving p<0.01 were considered

BiomarkerNerve function testsrP valueβP value
TNFSF12
(TWEAK)
Tibial MNCV0.1640.0050.1220.037
Peroneal MNCV0.2070.00030.1550.006
Sural SNCV0.244<0.00010.2080.0002
Sural SNAP0.259<0.00010.242<0.0001
Cold TDT hand0.226<0.00010.1950.001
TNFSF14
(LIGHT)
Peroneal MNCV0.1590.0060.1230.031
Sural SNCV0.2100.00030.1840.002
Sural SNAP0.2050.00040.1910.001
Cold TDT hand0.2140.00020.1310.029
Cold TDT foot0.1820.0020.1260.035
CCL20
(MIP-3α)
Metacarpal VPT0.1820.0020.1830.002
Warm TDT hand0.1650.0040.1820.002
CXCL1
(MGSA-α)
Cold TDT hand0.1680.0040.1240.035
DNERTibial MNCV0.227<0.00010.2170.0002
Peroneal MNCV0.228<0.00010.1760.002
Ulnar SNAP0.1660.0050.1940.001
MMP1Sural SNCV0.1720.0030.1500.008
Sural SNAP0.1770.0020.1680.003
  • Linear regression analyses were adjusted for sex, age, body mass index (BMI), HbA1c, smoking, and diabetes duration.

  • CCL, chemokine (C-C motif) ligand; CXCL1, chemokine (C-X-C motif) ligand 1; DNER, delta and Notch-like epidermal growth factor-related receptor; DSPN, diabetic sensorimotor polyneuropathy; LIGHT, homologous to lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes; MGSA-α, melanoma growth-stimulating activity alpha; MIP, macrophage inflammatory protein; MMP1, matrix metalloproteinase-1; MNCV, motor nerve conduction velocity; PROPANE, Probing the Role of Sodium Channels in Painful Neuropathy Study; SNAP, sensory nerve action potential; SNCV, sensory nerve conduction velocity; TDT, thermal detection threshold; TNFSF, tumor necrosis factor ligand superfamily; TWEAK, TNF-related weak inducer of apoptosis; VPT, vibration perception threshold.